Gremlin 2 is Repressed in Invasive Endometrial Cancer and Inhibits Cell Growth In Vitro
Hiroshi Tsubamoto1, Kazuko Sakata2, Riya Sakane2
1Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan tsuba@hyo-med.ac.jp.
Background:
There exist limited therapeutic opportunities regarding the treatment of endometrial cancer (EC), and novel therapies based on the molecular profiling of EC cells are required.
Materials And Methods:
We used microarray analysis of EC tumour samples in order to identify tumour-specific changes regarding gene expression.
Results:
It was found that gremlin 2, an inhibitor of bone morphogenetic protein (BMP) signaling, was repressed in EC samples, and that gremlin 2 inhibited tumour cell growth.
Conclusion:
Down-regulation of gremlin 2 may lead to carcinogenesis and progression of EC. We suggest that re-activation of gremlin 2-associated pathways could suppress EC progression and should thus be explored as a potential novel therapeutic approach.
Insights
Endometrial cancer (EC) shows repressed gremlin 2, a protein that inhibits tumor growth. Reactivating gremlin 2 pathways may offer a new therapeutic strategy for EC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Limited therapeutic options exist for endometrial cancer (EC).
- Novel therapies require molecular profiling of EC cells.
- Understanding EC molecular changes is crucial for treatment development.
Purpose of the Study:
- To identify tumor-specific gene expression changes in EC.
- To investigate the role of gremlin 2 in EC development and progression.
Main Methods:
- Microarray analysis of EC tumor samples.
- Gene expression profiling to identify differentially expressed genes.
Main Results:
- Gremlin 2, a bone morphogenetic protein (BMP) signaling inhibitor, was found to be repressed in EC samples.
- Gremlin 2 demonstrated inhibitory effects on EC tumor cell growth.
Conclusions:
- Down-regulation of gremlin 2 may contribute to EC carcinogenesis and progression.
- Re-activation of gremlin 2 pathways presents a potential therapeutic approach for EC.
- Targeting gremlin 2 signaling could suppress EC progression.
